BioPharmSignal logoBioPharmSignal

Biotech News

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus (ABUS)ArbutusEarnings

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Phase 1a/1b

Related news

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-03-23 11:30 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

BNTXBioNTech2026-05-05 10:45 EST

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

BNTXBioNTech2026-04-21 10:45 EST

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

COCPCocrystal Pharma2026-05-15 12:00 EST

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

AVIRAtea2026-05-12 20:06 EST

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

View all latest news

Arbutus

Hepatitis B Therapeutics Company Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen, and is being studied in combination regimens. Combination...

Recent company news

ABUSArbutus2026-07-16 11:30 EST

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

ABUSArbutus2026-04-15 11:30 EST

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

ABUSArbutus2026-03-23 11:30 EST

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

ABUSArbutus2026-03-03 21:15 EST

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Stock data

Close
4.54 USD
Market cap
841.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States